ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 3,524 call options on the company. This represents an increase of approximately 6,193% compared to the typical volume of 56 call options.
ImmunoPrecise Antibodies Stock Up 60.2 %
ImmunoPrecise Antibodies stock traded up $0.30 during midday trading on Wednesday, hitting $0.79. 246,571,867 shares of the stock were exchanged, compared to its average volume of 18,194,236. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85. The company has a 50 day moving average price of $0.44 and a two-hundred day moving average price of $0.60. The firm has a market cap of $24.54 million, a P/E ratio of -0.97 and a beta of 0.01. ImmunoPrecise Antibodies has a 1 year low of $0.32 and a 1 year high of $2.60.
ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) last issued its quarterly earnings results on Tuesday, December 10th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. On average, sell-side analysts predict that ImmunoPrecise Antibodies will post -0.27 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on ImmunoPrecise Antibodies
Institutional Trading of ImmunoPrecise Antibodies
An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC grew its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Free Report) by 20.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,558,892 shares of the company’s stock after purchasing an additional 263,451 shares during the period. Ingalls & Snyder LLC owned 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by hedge funds and other institutional investors.
ImmunoPrecise Antibodies Company Profile
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Recommended Stories
- Five stocks we like better than ImmunoPrecise Antibodies
- What Are Dividend Challengers?
- Netflix Adds 19 Million Subscribers, Growth Is Far For Over
- What is the Nasdaq? Complete Overview with History
- Tempus AI: A Game-Changer in AI-Powered Healthcare
- Most active stocks: Dollar volume vs share volume
- Pelosi Bets Big on AI: This Is What You Need to Know
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.